IDEAYA Biosciences, Inc. 8-K

What Happened
IDEAYA Biosciences, Inc. (IDYA) filed an 8-K reporting the results of its June 16, 2026 Annual Meeting of Stockholders and announcing Board leadership changes. As of the April 20, 2026 record date, 87,860,920 shares were outstanding. Stockholders voted to elect three Class I directors, ratify PricewaterhouseCoopers LLP as the company’s independent auditor for 2026, and approved, on a non‑binding basis, the compensation of named executive officers. Effective June 16, 2026, the Board elected Yujiro S. Hata as Chairman and Terry Rosen, Ph.D., as Lead Independent Director.

Key Details

• Shares outstanding and entitled to vote: 87,860,920 (record date April 20, 2026).
• Director elections (to hold office until 2029):
  • Yujiro S. Hata — For: 70,546,418; Withheld: 2,470,077; Broker non‑votes: 10,089,343.
  • M. Garret Hampton, Ph.D. — For: 56,718,637; Withheld: 16,297,858; Broker non‑votes: 10,089,343.
  • Catherine J. Mackey, Ph.D. — For: 70,281,521; Withheld: 2,734,974; Broker non‑votes: 10,089,343.
• Auditor ratification: PricewaterhouseCoopers LLP ratified — For: 82,579,758; Against: 141,240; Abstentions: 384,840.
• Advisory vote on executive compensation (non‑binding): For: 64,269,756; Against: 8,349,131; Abstentions: 397,608; Broker non‑votes: 10,089,343.

Why It Matters
These results confirm the company’s board composition and governance direction for the next term and formally ratify PwC as the independent auditor for 2026. The non‑binding approval of executive compensation indicates majority shareholder support for pay practices, while the Board’s appointment of Yujiro S. Hata as Chairman and Terry Rosen as Lead Independent Director updates the company’s leadership structure—items investors often watch for governance and oversight implications.